Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
Active, not recruiting · NCT03747120 · Registry updated 2026-07-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-07-08 | NCT03747120 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Breast Cancer Research Foundation | 40 |
| Merck Sharp & Dohme LLC | 650 |
| University of Texas Southwestern Medical Center | 295 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cedars Sinai Medical Center | Los Angeles | United States | 135 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| New Mexico Cancer Center | Albuquerque | United States | 4 |
| Providence Cancer Institute | Portland | United States | 17 |
| UT Southwestern Medical Center | Dallas | United States | 1 |